Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.39 |
| ▸ | NPY2R | P49146 | 2/20 | 0.39 |
| ▸ | NPY4R | P50391 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | BECN1 | Q14457 | 6/20 | 0.37 |
| ▸ | KRAS | P01116 | 4/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | F12 | P00748 | 2/20 | 0.35 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.35 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10138953 | 0.94 | NPY1R (0.41) | NPY1RNPY2RNPY4RNPY5RBECN1 | |
| SCHEMBL10138943 | 0.86 | SIRT2 (0.42) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL16480284 | 0.78 | TERF2IP (0.49) | NPY1RNPY2RNPY4RNPY5RBECN1 | |
| SCHEMBL14028877 | 0.77 | BECN1 (0.44) | NPY1RNPY2RNPY4RNPY5RBECN1 | |
| SCHEMBL16480282 | 0.74 | TERF2IP (0.50) | NPY1RNPY2RNPY4RNPY5RBECN1 | |
| SCHEMBL14028880 | 0.73 | TERF2IP (0.46) | NPY1RNPY2RNPY4RNPY5RBECN1 | |
| SCHEMBL14028885 | 0.73 | TERF2IP (0.45) | NPY1RNPY2RNPY4RNPY5RBECN1 | |
| SCHEMBL16480283 | 0.72 | SIRT2 (0.45) | NPY1RNPY2RNPY4RNPY5RTERF2IP | |
| SCHEMBL23351287 | 0.61 | NPY1R (0.53) | NPY1RNPY2RNPY4RNPY5RBECN1 | |
| SCHEMBL19473905 | 0.60 | TSLP (0.43) | KRASFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629241-B2 | Alpha helical mimics, their uses and methods for their production | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-01-14 | — | — | US | disclosed |
| US-20120238507-A1 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-09-20 | — | — | US | disclosed |
| US-8193310-B2 | Short chain peptide; conformation scaffolds; diecting amino acids into positions; controlling apoptosis; tumor suppression; alcoholism; drug abuse; antiepileptic agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238507-A1 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | CRYAA, PTMA, HIRA | NPY1R 649/4885NPY2R 1127/4885NPY4R 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.